300110
vs
S
Shanghai Composite
300110
Over the past 12 months, Huaren Pharmaceutical Co Ltd has underperformed Shanghai Composite, delivering a return of +9% compared to the Shanghai Composite's +28% growth.
Stocks Performance
300110 vs Shanghai Composite
Performance Gap
300110 vs Shanghai Composite
Performance By Year
300110 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Huaren Pharmaceutical Co Ltd
Glance View
Huaren Pharmaceutical Co., Ltd. engages in development, manufacture, and sale of non polyvinyl chloride and non-PVC large capacity preparations. The company is headquartered in Qingdao, Shandong and currently employs 2,242 full-time employees. The company went IPO on 2010-08-25. The firm provides basic infusion products, including sodium chloride infusions, dextrose infusions and compound sodium chloride infusions, among others; infusion products for treatment, including metronidazole and sodium chloride infusions, ciprofloxacin lactate and sodium chloride infusions and others, as well as nutritious infusion products, among others. The firm distributes its products in domestic market, with Northeast China as its main market.
